Danish pharmaceutical company Xellia is building a state-of-the-art, fully automated pharmaceutical plant in Szigetszentmiklós. The investment amounts to approximately HUF 28 billion (EUR 71 million), with one quarter covered by state subsidies.
With the investment, 91 highly skilled jobs will be created. The new facility of Xellia Gyógyszervegyészeti Kft. focuses on automation and digitalization, aiming to strengthen Hungary as a research and development hub in the long term. The project’s significance extends far beyond national borders. In the middle of global supply chain challenges, the plant will be a key component in ensuring the pharmaceutical supply security of the entire European Union. The facility will produce entirely for export, with an expected 90% share of inputs sourced from Hungarian suppliers.
Hungary’s pharmaceutical sector ranks among the top 20 largest medicine exporters worldwide. Over the past decade alone, three dozen major projects totaling HUF 260 billion (EUR 663 million) were launched, enabling the industry to increase its output last year to HUF 1,300 billion (EUR 3.3 billion). The pharmaceutical industry is considered a driver of Hungary’s economic structural transformation. With 36 international major investments over the past ten years, the sector is among the country’s most innovative industries.